Health Canada continues to monitor newly approved drugs to determine if the benefits identified in the pre-market trials hold up to further scrutiny. Canadians need better access to that information.
Academic rigor, journalistic flair
Articles on pharma companies
Displaying all articles
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
With lives depending on a vaccine, trust in Canada’s COVID-19 Vaccine Task Force is crucial. Members of the task force need to make any industry links or potential conflicts of interest publicly clear.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
An important new study in the United States has found doctors who receive just one cheap meal from a drug company tend to prescribe a lot more of that company’s products.
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Assistant Professor, Bond University
-
Assistant Professor, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto
-
Assistant Professor, Department of Family and Community Medicine, University of Toronto
-
Chief Scientist, Center for Bioethics and Humanities and Professor of Medicine and Public Health, University of Colorado Anschutz Medical Campus
-
Associate professor, School of Public Policy and Administration, Carleton University
